Molecular biology of oral sub mucous fibrosis

Saravanan, K.; Ram, Malathi; Ganesh, R

doi:10.4103/0973-1482.113340

Cited by 13 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abnormal expressions of some cytoskeleton proteins (eg, vimentin and cytokeratin) and ECM molecules (eg, tenascin, fibronectin, MMP‐2, MMP‐9, and PAI‐1) which are involved in EMT may be associated with these morphological changes. The likelihood of EMT in OSF is further supported by the fact that many cytokines (TGF‐β↑, bFGF↑, TNF‐α↑, IL‐1↑, PDGF↑, endothelin‐1↑, IGF↑, ZEB1/2↑, SNAIL↑, and TWIST1/2↑), nucleus proteins (Smad‐2/3↑ and NF‐κB↑), and signaling pathways (MAPK, NF‐κB, Hedgehog, Notch, Wnt, and TGF‐β pathways) involved in EMT were expressed and activated in OSF . For example, TWIST, a basic helix‐loop‐helix domain‐containing transcription factor, functions as a transcription repressor to activate EMT traits by repressing the expression of epithelial marker E‐cadherin .…”

Section: Pathogenesismentioning

confidence: 98%

“…The likelihood of EMT in OSF is further supported by the fact that many cytokines (TGF-β↑, bFGF↑, TNF-α↑, IL-1↑, PDGF↑, endothelin-1↑, IGF↑, ZEB1/2↑, SNAIL↑, and TWIST1/2↑), nucleus proteins (Smad-2/3↑ and NF-κB↑), and signaling pathways (MAPK, NF-κB, Hedgehog, Notch, Wnt, and TGF-β pathways) involved in EMT were expressed and activated in OSF. 16 For example, TWIST, a basic helix-loop-helix domain-containing transcription factor, functions as a transcription repressor to activate EMT traits by repressing the expression of epithelial marker E-cadherin. 17…”

Section: Epithelial Mesenchymal Transitionmentioning

confidence: 99%

See 1 more Smart Citation

Oral submucous fibrosis in Asian countries

Peng

Chen

et al. 2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

Oral submucous fibrosis (OSF) is a chronic, insidious, and progressive oral mucosal disease that affects entire oral cavity and sometimes pharynx. It is precancerous and characterized by blanching and burning sensation of oral mucosa, staining of teeth and gingiva, and restricted mouth opening. It is multifactorial with a high incidence in chewers of areca nut (AN). This oral potentially malignant disorder has a high rate of malignant transformation rate (7%-30%) to oral squamous cell carcinoma (OSCC). 1 It is prevalent in Asian countries and has spread in Europe and North America. The prevalence of OSF was reported to be 1.0%-3.03% in Hunan Province, mainland China, 2 0.15%-14.4% in Vietnam, 3 and 0.086%-17.6% in Taiwan. 4 In the past decades, many efforts have been devoted to etiology, pathogenesis, and treatment of OSF. However, the research progress is still unsatisfactory. For instance, the etiology of OSF is commonly attributed to AN chewing, but some OSF patients did not have the habit. Also, there is no staging or grading scheme universally accepted and employed by clinicians, pathologists, and surgeons. Moreover, the pathogenesis and mechanism of OSF transformation into carcinomas are still obscure. Undoubtedly, it is crucial to make further studies of OSF to fill in the gaps. This article, for the first time, provided a detailed review of research advances of OSF in Asian countries, based on a comprehensive literature search using several primary databases (Figure 1), in which the terminologies, for example, OSF and oral potential malignant diseases (OPMD), were used. The OSF's etiology, histopathology, pathogenesis, clinical manifestations, diagnosis and differential diagnosis, and treatments were reviewed. The main challenges and corresponding measures were also discussed for guiding clinical research and practice concerning the disease. | E TI O LO GYOral submucous fibrosis is characterized by its multifactorial etiology. The most commonly identified factors include AN chewing, nutritional disorders, and genetic predisposition. They act individually or synergistically in the development of OSF. AbstractOral submucous fibrosis (OSF) is a chronic, insidious, and progressive oral mucosal disease that affects entire oral cavity and sometimes pharynx. This oral potentially malignant disorder has a high rate of malignant transformation (7%-30%) to oral squamous cell carcinoma (OSCC), posing global problems for public health. Due to enormous efforts dedicated to this disease in the past decades, there have been significant advances in identification of its etiology and pathogenesis as well as development of corresponding therapeutic approaches, in spite of several challenges. This study reviewed the existing literature concerning OSF in Asian countries, encompassing its etiology, histopathology, pathogenesis, clinical manifestations, diagnosis and differential diagnosis, and treatments. For improving treatment of OSF, the multifactorial etiology analysis, incorporation of effective molecular pathways, cy...

show abstract

Section: Pathogenesismentioning

confidence: 98%

Section: Epithelial Mesenchymal Transitionmentioning

confidence: 99%

Oral submucous fibrosis in Asian countries

Peng

Chen

et al. 2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…The main pathological manifestation of OSF is abnormal accumulation of collagen in the lamina propria under the oral mucosa [ 8 ]. Following development of OSF, 3–19% of patients may develop cancer, and this probability increases yearly [ 9 ]. The habit of chewing areca nuts is considered to be the most likely factor for the occurrence and malignancy of OSF [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Egr-1 mediates low-dose arecoline induced human oral mucosa fibroblast proliferation via transactivation of Wnt5a expression

Chen

Jiao

Wang

et al. 2020

BMC Mol and Cell Biol

View full text Add to dashboard Cite

Background Arecoline is an alkaloid natural product found in the areca nut that can induce oral submucous fibrosis and subsequent development of cancer. However, numerous studies have shown that arecoline may inhibit fibroblast proliferation and prevent collagen synthesis. Results High doses of arecoline (> 32 μg/ml) could inhibit human oral fibroblast proliferation, while low doses of arecoline (< 16 μg/ml) could promote the proliferation of human oral fibroblasts. Wnt5a was found to be both sufficient and necessary for the promotion of fibroblast proliferation. Egr-1 could mediate the expression of Wnt5a in fibroblasts, while NF-κB, FOXO1, Smad2, and Smad3 did not. Treatment with siRNAs specific to Egr-1, Egr inhibitors, or Wnt5a antibody treatment could all inhibit arecoline-induced Wnt5a upregulation and fibroblast proliferation. Conclusions Egr-1 mediates the effect of low dose arecoline treatment on human oral mucosa fibroblast proliferation by transactivating the expression of Wnt5a. Therefore, Egr inhibitors and Wnt5a antibodies are potential therapies for treatment of oral submucosal fibrosis and oral cancer.

show abstract

“…The main pathological manifestation of OSF is abnormal accumulation of collagen in the lamina propria under the oral mucosa [26]. With the development of OSF, 3%-19% of patients may have cancer, and this probability increases year by year [27]. The habit of chewing areca nut is considered to be the most likely factor for the occurrence and malignant progress of OSF [28].…”

Section: Discussionmentioning

confidence: 99%

Egr-1 mediates low dose Arecoline induced human oral mucosa fibroblasts proliferation by transaction the expression of Wnt5a

Chen¹,

Jiao²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Arecoline is the main carcinogens in Areca nut that induce oral submucous fibrosis to develop into cancer. However, many previous studies have showed that Arecoline may inhibit proliferation and prevent collagen synthesis of fibroblasts. Results High dose Arecoline (> 32 µg/ml) could inhibit but low dose Arecoline (< 16 µg/ml) could promote the proliferation of human oral fibroblasts. Wnt5a was both sufficient and necessary for the promotion of fibrobasts proliferation. Egr-1, but not NF-κB, FOXO1, Smad2 or Smad3, mediated the expression of Wnt5a in fibrobasts. The specific siRNAs of Egr-1, Egr inhibitors or Wnt5a antibodies treatment blocked Arecoline induced Wnt5a upregulation and fibroblasts proliferation. Conclusions Egr-1 mediates low dose Arecoline induced human oral mucosa fibroblasts proliferation by transaction the expression of Wnt5a, and Egr inhibitors or Wnt5a antibodies are potential therapeutic drugs of oral submucosal fibrosis and oral cancer.

show abstract

Molecular biology of oral sub mucous fibrosis

Cited by 13 publications

References 8 publications

Oral submucous fibrosis in Asian countries

Oral submucous fibrosis in Asian countries

Egr-1 mediates low-dose arecoline induced human oral mucosa fibroblast proliferation via transactivation of Wnt5a expression

Egr-1 mediates low dose Arecoline induced human oral mucosa fibroblasts proliferation by transaction the expression of Wnt5a

Contact Info

Product

Resources

About